Alisha Cooley, APRN
Family · Somerset, KYNPI 1851699060
Payments from drug & device makers
Across 124 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$715
- Lilly USA, LLC$170
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$164
- GSK$94
- Mylan Specialty L.p.$82
- Takeda Pharmaceuticals U.S.A., Inc.$73
- plus $728 from 23 others
What the payments were for
- Food & beverage$2,026100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $715 |
| Lilly USA, LLC | 11 | $170 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $164 |
| GSK | 5 | $94 |
| Mylan Specialty L.p. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Novartis | 4 | $63 |
| Astellas Pharma US Inc | 4 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Nestle Healthcare Nutrition Inc. | 3 | $54 |
| Pfizer | 3 | $43 |
| Cipher Pharmaceuticals US LLC | 1 | $40 |
| AstraZeneca | 2 | $39 |
| Alkermes, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Mylan Institutional Inc. | 1 | $33 |
| Fresenius Kabi USA, LLC | 2 | $28 |
| Almatica Pharma LLC | 1 | $24 |
| Medtronic | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 2 | $18 |
| Neurelis, Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| QOL Medical, LLC | 1 | $12 |
How this compares
$2,026 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $111,153 |
| EliquisApixaban | 131 | $69,931 |
| MounjaroTirzepatide | 50 | $57,430 |
| LinzessLinaclotide | 75 | $47,897 |
| FarxigaDapagliflozin Propanediol | 86 | $36,718 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $25,759 |
| EntrestoSacubitril/Valsartan | 36 | $17,398 |
| XareltoRivaroxaban | 35 | $15,543 |
| JardianceEmpagliflozin | 16 | $14,165 |
| VascepaIcosapent Ethyl | 56 | $14,005 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,620 |
| Dexlansoprazole DrDexlansoprazole | 36 | $8,493 |
| Levothyroxine Sodium | 599 | $7,220 |
| MyrbetriqMirabegron | 19 | $6,758 |
| Atorvastatin Calcium | 492 | $6,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $15 | $111,153103 claims |
| PfizerEliquis | $43 | $69,931131 claims |
| Lilly USA, LLCMounjaro | $170 | $57,43050 claims |
| AbbVieLinzess | $715 | $47,89775 claims |
| AstraZenecaFarxiga, Symbicort | $39 | $42,886110 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $94 | $38,37956 claims |
| NovartisEntresto | $63 | $17,39836 claims |
| Johnson & JohnsonXarelto | $15 | $15,54335 claims |
| Boehringer IngelheimJardiance | $15 | $14,16516 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $6,75819 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $1,686150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.
Other family in Somerset
- Miranda WithersSomerset$17K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.